Evidence map›Paper›PMID 34699082›Full record

ArticleVox sanguinis2022

Evaluation of prophylactic polyclonal anti-D antibodies: Differences in Fc-glycosylation in commercial products.

Filippo Mori, Alfonso Salvatore, Ester Ascione, Raffaele Di Marzo, Bernard Fox

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Vox sanguinis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Filippo MoriDepartment of Research and Innovation, Kedrion S.p.A., Lucca, Italy.ORCID 0000-0001-8940-5415
Alfonso SalvatoreDepartment of Industrial Development, Kedrion S.p.A., Naples, Italy.
Ester AscioneDepartment of Industrial Development, Kedrion S.p.A., Naples, Italy.
Raffaele Di MarzoTherapeutic Area Lead, Global Medical Affairs Department, Kedrion S.p.A., Lucca, Italy.
Bernard FoxBiotherapeutics Division, National Institute for Biological Standards and Control (NIBSC), Potters Bar, Herts, UK.ORCID 0000-0001-6362-5196

Funding

This study was funded by Kedrion Biopharma Inc.
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Immunoglobulin GRho(D) Immune GlobulinGlycosylationHumansImmunoglobulin Fc FragmentsImmunoglobulin Fc FragmentsImmunoglobulin GRHO(D) antibodyRho(D) Immune Globulin

Identifiers

PMID34699082
PMCPMC9298374

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.